mRNA疫苗的开发及临床研究进展  

Development and Clinical Progress of mRNA Vaccine

作　　者：胡瞬[1,2,3,4] 易有金 胡涛[3] 李福胜[2] HU Shun;YI You-jin;HU Tao;LI Fu-sheng(College of Food Science and Technology,Hunan Agricultural University,Changsha 410128,China;Kangzhong(Beijing)Biotechnology Co.,Ltd.,Beijing 100176,China;Institute of Process Engineering,Chinese Academy of Sciences,Beijing 100190,China;School of Public Healthy,Xiangnan University,Chenzhou 423000,China)

机构地区：[1]湖南农业大学食品科学技术学院,长沙410128 [2]康众(北京)生物科技有限公司,北京100176 [3]中国科学院过程工程研究所,北京100190 [4]湘南学院公共卫生学院,郴州423000

出　　处：《中国生物工程杂志》2019年第11期105-112,共8页China Biotechnology

摘　　要：随着mRNA稳定性和安全高效的递送系统的研究日渐成熟,近年来,mRNA疫苗在肿瘤个体化疫苗中取得了较大进展,因其生产工艺简单、在细胞内表达抗原、安全性优于DNA疫苗等特点,是一种很有前途的新型疫苗。为了解全球mRNA疫苗的开发与研究现状,在此重点对mRNA疫苗的分子设计、递送系统、临床研究现状进行了分析和综述,为后续mRNA疫苗的开发和研究提供参考依据。As the increasingly develepoment of mRNA stability and delivery systems,the mRNA vaccine has made rapid progress in the individualized tumor vaccine in recent years.Due to its simple production process,expression the antigens in cells,and security features is superior to DNA vaccine,mRNA is a new form of vaccine promising alternative to attenuated and inactivated vaccine and protein vaccine.In order to understand the development and research status of global mRNA vaccine,the molecular design,delivery system and clinical research status of mRNA vaccine were analyzed and summarized,providing reference for the subsequent development and research of mRNA vaccine.

关 键 词：mRNA疫苗 递送系统 临床试验 

分 类 号：Q819[生物学—生物工程]